The study calls for a well regulated OTC framework that not only helps improve access to medicines but also supports responsible self-medication to achieve multiple health and economic objectives, OPPI said in a statement.
"Access to medicines in India has long ignored the critical role of the viability of OTC medicines in the remotest areas. A well-regulated OTC guideline will expand access for patients," President-OPPI and MD India & VP - South Asia, Glaxo SmithKline Pharmaceuticals A Vaidheesh said.
The study, 'Shaping India's OTC Policy 2018' is an illustration of the collaborative effort of the entire pharmaceutical industry in empowering patients to make responsible and wise choices and self-manage their health outcomes, he added.
The study also recommended the need for essential parameters such as quality, safety and efficacy standards to remain the same as for "Prescription" drugs, it added.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)